The recent development of a powerful and flexible genome editing technique (the CRISP-cas9 method) accelerates tremendously the production of animal models and will significantly enhance the perspectives of (somatic) gene ...

Two clinical trials using CRISPR technology to engineer the T cells of cancer patients by inactivating the gene for immune checkpoint molecule PD-1 are (almost) underway, one in the USA and the other in China. The less ...

Targeted modification of genes (“gene editing”) is made much easier by the recently developed CRISPR-Cas9 system. This has raised alarm about possible uses of this technology for germline modification of the human genome; ...

A Genome Wide Association Study on propensity to motion sickness published by 23andMe gives interesting results, shows validity for self-reported phenotypic information and underlines the value of the model developed by ...

Analysing the data recently presented by Jiankui He and assuming that it is authentic shows that the goal of abolishing the expression of CCR5 may have been reached for one of the resulting twins, although this remains to ...

A new approach, based on the use of peptide nucleic acid molecules to form triple helices and promote locus-specific recombination, demonstrates potential for in vivo gene correction at clinically significant levels and ...

The planned acquisition of Pacific Biosciences by Illumina could signal a big change in the DNA sequencing landscape, and provides the incentive for an update on a field that still has a number of players and could be ...

The first therapy based on chimeric antigen receptors has been approved by the FDA. It gives excellent results in recurrent paediatric ALL; its cost is very high but fairly consistent with the clinical benefit (long term ...

A novel gene editing procedure based on a nuclease from the Argonaute protein family was described in mid-2016 and appeared to provide significant advantages over the now widely used CRISPR-Cas9 system. Attempts by numerous ...